Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: ARCT stock price vs CTMX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CTMX's multiple
Needs CTMX P/S.
Implied fair value · at ARCT's multiple
Needs ARCT P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ARCT FY 2025 (ended Dec 31, 2025) · CTMX FY 2025 (ended Dec 31, 2025).
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
ARCTURUS THERAPEUTICS HOLDINGS INC. · implied price per share
Bear
-$2.12
Base
-$2.50
Bull
-$2.87
CytomX Therapeutics, Inc. · implied price per share
Bear
$0.44
Base
$0.52
Bull
$0.60
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.47x
0.03x
Net debt / EBITDA
Leverage against operating earnings
2.04x
20.51x
Cash and equivalents
Liquid reserves on the balance sheet
$230.91M
$292.06M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
ARCT vs MRNA
BioNTech SE
ARCT vs BNTX
ALNYLAM PHARMACEUTICALS, INC.
ARCT vs ALNY
Sarepta Therapeutics, Inc.
ARCT vs SRPT
Intellia Therapeutics, Inc.
ARCT vs NTLA
IDEAYA Biosciences, Inc.
ARCT vs IDYA
EXELIXIS, INC.
ARCT vs EXEL
GILEAD SCIENCES, INC.
ARCT vs GILD
AMGEN INC
ARCT vs AMGN
AbbVie Inc.
ARCT vs ABBV
BRISTOL MYERS SQUIBB CO
ARCT vs BMY
$101.29M
$2.99M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
